Full-Time

Director – Finance and Strategic Modeling

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$204k - $255kAnnually

+ Equity Awards + Cash Compensation + Learning and Development Opportunities

Expert

San Carlos, CA, USA

This is a hybrid position, indicating that some in-office presence is required.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Excel/Numbers/Sheets
Financial Modeling

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree and 10+ years of relevant experience in finance, banking, and/or consulting.
  • Advanced excel-based modelling experience.
  • Strong analytical and strategic thinking skills.
  • Excellent written and verbal communication skills.
  • Ability to lead teams and collaborate cross-functionally.
  • Initiative-taking and able to work independently.
  • Resourceful, motivated, and able to identify potential issues or problems and find solutions.
Responsibilities
  • Create and maintain financial models (P&L, Valuation, NPV, DCF) that help guide near and long-term portfolio planning and decision making.
  • Provide finance support and develop financial models to assist in business development and corporate strategy efforts.
  • Assist in maintenance and update of the long-range financial model.
  • Conduct scenario and sensitivity analyses.
  • Support and provide financial insights for portfolio planning and prioritization.
  • Deliver clear, articulate analyses and insights to inform decisions for single assets and larger portfolio.
  • Effectively partner with multiple functions to align on key assumptions, including commercial organization for revenue projections and program management for probability of technical and regulatory success (PTRS).
  • Ad-hoc financial analysis support.
Desired Qualifications
  • Experience in oncology.
  • Biotech/Pharma industry experience.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity